Frampton Adam E, Giovannetti Elisa, Jamieson Nigel B, Krell Jonathan, Gall Tamara Mh, Stebbing Justin, Jiao Long R, Castellano Leandro
Department of Surgery and Cancer, HPB Surgical Unit, Imperial College, Hammersmith Hospital campus, Du Cane Road, London, W12 0HS, UK.
Expert Rev Mol Diagn. 2014 Apr;14(3):267-71. doi: 10.1586/14737159.2014.893192. Epub 2014 Feb 28.
Due to its aggressive and late presentation, there is an urgent need for novel and reliable biomarkers for the diagnosis and prognostication of pancreatic ductal adenocarcinoma (PDAC). MiRNAs have been extensively profiled in PDAC tissues, biopsies, blood samples and other biofluids and their expression levels compared to normal and chronic pancreatitis (CP) specimens in order to identify the most relevant candidates. Consolidation of these activities has not been attempted until now. The evaluated meta-review by Ma et al. helps to define the use of miRNAs as biomarkers for detecting this tumor-type and predicting survival outcomes in PDAC. Based on frequency and consistency between microarray studies, they identified a miRNA meta-signature for recognising PDAC: upregulation of miR-21, 23a, 31, 100, 143, 155, and 221; with downregulation of miR-148a, 217 and 375. Furthermore, they validated high miR-21, high miR-31 and low miR-375 tumoural expression as independently prognostic for poor overall-survival (OS; n = 70).
由于胰腺导管腺癌（PDAC）具有侵袭性且出现较晚，因此迫切需要用于其诊断和预后评估的新型可靠生物标志物。已对PDAC组织、活检样本、血液样本及其他生物流体中的微小RNA（miRNA）进行了广泛分析，并将其表达水平与正常及慢性胰腺炎（CP）样本进行比较，以确定最相关的候选物。此前尚未尝试整合这些研究成果。Ma等人所做的评估性荟萃综述有助于明确将miRNA用作检测这种肿瘤类型及预测PDAC生存结果的生物标志物。基于微阵列研究之间的频率和一致性，他们确定了一种用于识别PDAC的miRNA元特征：miR-21、23a、31、100、143、155和221上调；miR-148a、217和375下调。此外，他们验证了肿瘤中高表达的miR-21、高表达的miR-31和低表达的miR-375可独立预测总生存期（OS；n = 70）较差。
